121results about How to "No side effect" patented technology

This invention provides compounds which are represented by a general formula [I]

[in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3–10 membered aliphatic nitrogen-containing heterocyclic group; R³, R⁴ and R⁵ may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

Indirect method invocation of methods that only return constant values is optimized using fetching operations and return constant tables. Such method calls can be optimized if all possible method calls via the call site instruction return a constant value and have no side effects. Each constant return value is loaded from a return constant table, and method invocation is eliminated. If all possible target methods in a program result in a constant return value and have no side effects, an associated virtual function dispatch table (vtable) may be used as the return constant table. Furthermore, control operation optimization may be applied to identify type constraints, based on one or more possible type-dependent constant return values from an indirect method invocation. An optimizer identifies and maps between a restricted set of values and an associated restricted set of types on which execution code may operate relative to a given control operation. The type constraints are used to optimize the associated execution code by filtering propagation of runtime type approximations for optimization.

An object of the present invention is to provide safe therapeutic agents for asthma inhibiting the delayed type asthmatic reaction in bronchial asthma and having no side effect. The present invention is a therapeutic agents for asthma containing a compound represented by the under chemical formula or a physiologically acceptable base thereof as an effective ingredient, and the drug containing creatine or a physiologically acceptable base thereof as an effective ingredient.

Provided is a color light therapy device. The color light therapy device includes: a body that is used by being attached to a color light therapy portion of a human body by using a double-sided adhesive tape, a hydrogel pad, or an air suction plate, and includes a printed circuit board (PCB) that supplies driving power to a light source that emits color light in a given wavelength range to perform color light therapy on the human body; and a power jack that is connected to the PCB of the body through an electric wire. Since a user may use the color light therapy device by connecting the power jack to a mobile phone, a PC, a laptop, a tablet PC, a smartphone, a personal digital assistant (PDA), a vehicle, or a socket at home while carrying the color light therapy device, anyone may conveniently use the color light therapy device to perform color light therapy on the human body without exchanging or charging a battery.

Disclosed are uses of rare earth element selected from the group consisting of cerium (Ce), praseodymium (Pr), promethium (Pm), europium (Eu), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), scandium (Sc), yttrium (Y), lanthanum (La), neodymium (Nd), samarium (Sm), gadolinium (Gd), ruthenium (Lu) and mixtures thereof, or a salt or an oxide thereof for preventing hair loss, promoting hair regrowth and hair growth, removing and preventing dandruff, or promoting black hair formation.

The present invention relates to a synergistic herbal formulation comprising an active fraction from Azadirachta indica designated as Fraction A and a fraction from Citrullus colocynthis designated as Fraction B, along with a fraction C containing an antioxidant from Cucumis sativus extract; and pharmaceutically accepted a carrier wherein the ratio of the components ranging between about 2 to 5.5% of fraction A; about 0.5 to 2.5% of fraction B; about 0.1-0.4% of extract of Cucumis sativus; and about 82-97% of carrier or additive.

A device for preventing and treating myopia includes a base, a spectacles frame (1), a holder (3) and a lens (2). The holder (3) is mounted on the base; a visual target (4) is placed on the base. The spectacles frame (1) is connected to the holder (3) by adjustable connecting parts (31,32,33,34,35), so the distance between the spectacles frame (1) and the visual target (4) which is placed on the base is adjustable.

The present invention provides a prophylactic/therapeutic agent for an allergic disease caused by Th2 cell-polarized activation, which comprises at least one kind selected from a branched amino acid, glycine, serine, arginine, a keto acid thereof and a salt thereof. Because the prophylactic/therapeutic agent of the present invention produces almost no side effects, it can be safely ingested routinely and can be taken for a long time. When the prophylactic/therapeutic agent of the present invention is used in combination with an anti-inflammatory drug, the dose of the anti-inflammatory drug can be reduced. Hence, the prophylactic/therapeutic agent of the present invention is useful for the prevention or treatment of an allergic disease caused by Th2 cell-polarized activation. The prophylactic/therapeutic agent of the present invention is particularly effective on bronchial asthma and pulmonary fibrosis that accompanies bronchial asthma.

Provided are a pancreas perfusion apparatus capable of administering a drug only to the pancreas and strictly suppressing a leakage of the drug outside the pancreas and a method for controlling the same. The apparatus includes: a first vein occlusion section occluding a vein through which a venous blood from the pancreas flows; a second vein occlusion section occluding a vein into which a venous blood from collateral pathways outside the pancreas flows; an artery occlusion section occluding sites where an artery that nourishes the pancreas is connected to arteries that nourish other tissues; a drug administration section recovering a liquid upstream of the first vein occlusion section and supplying the recovered liquid to the artery; a systemic circulation section recovering a liquid upstream of the second vein occlusion section and feeding the recovered liquid into a systemic circulation; and a control device controlling the systemic circulation pump.

The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated plant materials that are soluble on wound surfaces.

The present invention is referred to an endoscopic implantable device for the apposition of the stomach walls for reducing the stomach internal volume, comprising a cylindrical elongated body comprising two hinged halves, each of which having a plurality of suction nozzles and a set of aligned grabbing teeth. Said suction nozzles have a fluid communication with a suction port of the endoscopic apparatus used to place said device into the patient's stomach, and the mentioned teeth of each half cooperate between each other to grab and keep the walls of the stomach together until the device is dissolved by the gastric fluids present in the stomach. The purposed invention also comprises a method for joining internal body tissue.

The invention relates to apparatus and methods for apparatus for detecting presence or monitoring profession of a disease in a biological subject, comprising a chamber in which the biological subject passes through, and at least one detection transducer in the chamber; wherein at least two types of information among the chemical composition, cellular classification, and molecular classification of the biological subject, are detected and collected for analysis as to whether the disease is likely to be present or progressing with the biological subject.

The present invention relates to a cosmetic composition for skin whitening comprising a small molecule-peptide conjugate. More specifically, it concerns the cosmetic composition for skin whitening comprising Caffeic acid-LG-NH₂ or Coumaric acid-LG-NH₂ as an active ingredient, which inhibits tyrosinase activity and melanin production, thereby showing an excellent skin whitening effect, and having no side effects to the skin by using a peptide component.